Kainos Medicine Inc (284620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kainos Medicine Inc (284620) has a cash flow conversion efficiency ratio of -0.551x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.01 Million USD) by net assets (₩5.40 Billion ≈ $3.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kainos Medicine Inc market capitalisation for the company's overall valuation and market capitalisation.
Kainos Medicine Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Kainos Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kainos Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kainos Medicine Inc ranked by their cash flow conversion efficiency. Explore 284620 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CJ Century Logistics Holdings Bhd
KLSE:7117
|
0.091x |
|
Morgan Sindall Group PLC
LSE:MGNS
|
-0.017x |
|
Times Guaranty Limited
NSE:TIMESGTY
|
-0.017x |
|
Gillanders Arbuthnot & Company Limited
NSE:GILLANDERS
|
0.008x |
|
Nextplat Corp
NASDAQ:NXPL
|
0.066x |
|
Canfor Pulp Products Inc.
TO:CFX
|
-0.064x |
|
Gabriel Resources Ltd
V:GBU
|
0.080x |
|
KebNi AB (publ)
ST:KEBNI-B
|
0.158x |
Annual Cash Flow Conversion Efficiency for Kainos Medicine Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Kainos Medicine Inc from 2017 to 2024. View 284620 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩1.79 Billion ≈ $1.21 Million |
₩-9.71 Billion ≈ $-6.58 Million |
-5.430x | -348.73% |
| 2023-12-31 | ₩11.75 Billion ≈ $7.96 Million |
₩-14.22 Billion ≈ $-9.64 Million |
-1.210x | -179.71% |
| 2022-12-31 | ₩26.11 Billion ≈ $17.69 Million |
₩-11.30 Billion ≈ $-7.66 Million |
-0.433x | +43.05% |
| 2021-12-31 | ₩12.10 Billion ≈ $8.20 Million |
₩-9.20 Billion ≈ $-6.23 Million |
-0.760x | -23.35% |
| 2020-12-31 | ₩12.35 Billion ≈ $8.37 Million |
₩-7.61 Billion ≈ $-5.16 Million |
-0.616x | -3385.22% |
| 2019-12-31 | ₩9.91 Billion ≈ $6.71 Million |
₩185.74 Million ≈ $125.88K |
0.019x | +937.07% |
| 2018-12-31 | ₩9.83 Billion ≈ $6.66 Million |
₩-22.01 Million ≈ $-14.92K |
-0.002x | +92.18% |
| 2017-12-31 | ₩950.59 Million ≈ $644.20K |
₩-27.23 Million ≈ $-18.45K |
-0.029x | -- |
About Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more